DK2983784T3 - Sammensætning, der omfatter hip/pap-protein eller et derivat deraf, til behandling af insulinresistens - Google Patents

Sammensætning, der omfatter hip/pap-protein eller et derivat deraf, til behandling af insulinresistens Download PDF

Info

Publication number
DK2983784T3
DK2983784T3 DK14720662T DK14720662T DK2983784T3 DK 2983784 T3 DK2983784 T3 DK 2983784T3 DK 14720662 T DK14720662 T DK 14720662T DK 14720662 T DK14720662 T DK 14720662T DK 2983784 T3 DK2983784 T3 DK 2983784T3
Authority
DK
Denmark
Prior art keywords
derivative
treatment
insulin resistance
composition including
pap protein
Prior art date
Application number
DK14720662T
Other languages
English (en)
Inventor
Fabrizio Andreelli
Paul Amouyal
Christophe Magnan
Céline Cruciani-Guglielmacci
Jamila Faivre
Christian Brechot
Gilles Amouyal
Marion Darnaud
Laure Jamot
Original Assignee
The Healthy Aging Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Healthy Aging Company filed Critical The Healthy Aging Company
Application granted granted Critical
Publication of DK2983784T3 publication Critical patent/DK2983784T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK14720662T 2013-04-10 2014-04-04 Sammensætning, der omfatter hip/pap-protein eller et derivat deraf, til behandling af insulinresistens DK2983784T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353245A FR3004354A1 (fr) 2013-04-10 2013-04-10 Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
PCT/FR2014/050821 WO2014167230A1 (fr) 2013-04-10 2014-04-04 Composition comprenant la protéine hip/pap ou l'un de ses dérivés pour le traitement de la résistance à l'insuline

Publications (1)

Publication Number Publication Date
DK2983784T3 true DK2983784T3 (da) 2019-11-25

Family

ID=49151035

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14720662T DK2983784T3 (da) 2013-04-10 2014-04-04 Sammensætning, der omfatter hip/pap-protein eller et derivat deraf, til behandling af insulinresistens

Country Status (9)

Country Link
US (1) US9629896B2 (da)
EP (1) EP2983784B1 (da)
JP (2) JP6890970B2 (da)
CN (1) CN105658280B (da)
DK (1) DK2983784T3 (da)
ES (1) ES2755177T3 (da)
FR (1) FR3004354A1 (da)
PL (1) PL2983784T3 (da)
WO (1) WO2014167230A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
CA3070182A1 (en) * 2017-07-13 2019-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reg3alpha for use in the protection of oxygen sensitive gram-positive bacteria
CN107936111B (zh) * 2017-12-16 2021-09-07 广州安辰新药研究院有限公司 一种hip/pap蛋白的制备方法
EP4252766A1 (en) * 2022-04-01 2023-10-04 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating and/or preventing a disorder characterized by a high cxcl5 serum level in an individual

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094958A1 (en) * 2002-05-09 2003-11-20 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1891972A1 (en) * 2005-04-26 2008-02-27 Stelic Institute of Regenerative Medicine Agent for promoting hepatic cell replication and agent for improving insulin resistance
CA2609667C (en) 2005-05-25 2011-02-22 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
ES2399147T3 (es) * 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
EP2260857A1 (en) * 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline

Also Published As

Publication number Publication date
CN105658280B (zh) 2020-05-15
CN105658280A (zh) 2016-06-08
US20160058833A1 (en) 2016-03-03
FR3004354A1 (fr) 2014-10-17
JP2016518354A (ja) 2016-06-23
ES2755177T3 (es) 2020-04-21
US9629896B2 (en) 2017-04-25
WO2014167230A1 (fr) 2014-10-16
PL2983784T3 (pl) 2020-06-15
EP2983784A1 (fr) 2016-02-17
JP6890970B2 (ja) 2021-06-18
EP2983784B1 (fr) 2019-09-11
JP2020007365A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
DK3397321T3 (da) Autoinjektor med temperaturstyring
DK3134151T3 (da) Sprøjte med rullemembran
DK3140008T3 (da) Hurtigtvirkende insulinsammensætninger
DK3692857T3 (da) Indretning til levering af hudplejesammensætning
DK3545906T3 (da) Indretning til udskiftning af hjerteklap
DK3003075T3 (da) Kit til inhalering af fordampede substanser
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK2903967T3 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme
DK3155017T3 (da) Forbedrede lægemidler til insulinresistens
DK2867230T3 (da) Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
DK3193978T3 (da) Lægemiddelinjektor af hudplastertypen til voluminøs bolus med medikamentforvarmning
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3256804T3 (da) Sinterovn til komponenter af sintermateriale, særligt dentalkomponenter
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
FI20155027A (fi) Polymyksiinijohdannainen ja sen käytöt
DK2992953T3 (da) Fremgangsmåde til fremstilling af en mikroindkapsling, mikroindkapsling og sammensætning
DK2983784T3 (da) Sammensætning, der omfatter hip/pap-protein eller et derivat deraf, til behandling af insulinresistens
DK2956237T3 (da) Fremgangsmåde til fremstilling af en sammensætning til fugtregulering
DK3368627T3 (da) Klæbemiddelsammensætning
DK3148993T3 (da) Fremgangsmåde til fremstilling af thiazolderivater
DK2978414T3 (da) Sammensætning omfattende hydrocortison